769109-13-9

Usage

Uses

Used in Pharmaceutical Applications:
Imidazo[1,2-b]pyridazine-6-carboxylic acid (9CI) is utilized as an enzyme inhibitor in pharmaceutical research and development. Its specific biological activity makes it a candidate for the treatment of various conditions by targeting and modulating the activity of specific enzymes involved in disease pathways.
Used in Organic Synthesis:
In the field of organic synthesis, Imidazo[1,2-b]pyridazine-6-carboxylic acid (9CI) serves as a key intermediate or building block for the synthesis of more complex organic molecules. Its unique structure allows for the creation of novel compounds with potential applications in various industries.
Used in Material Science:
Imidazo[1,2-b]pyridazine-6-carboxylic acid (9CI) is employed in material science for the development of new materials with specific properties. Its incorporation into materials can lead to advancements in areas such as electronics, sensors, and other high-tech applications.
Further research is essential to fully explore the potential applications and mechanisms of action of Imidazo[1,2-b]pyridazine-6-carboxylic acid (9CI), ensuring its safe and effective use across different industries.

InChI:InChI=1/C7H5N3O2/c11-7(12)5-1-2-6-8-3-4-10(6)9-5/h1-4H,(H,11,12)

Upstream product

• 1234616-21-7 imidazo[1,2-b]pyridazine-6-carboxylic acid methyl ester 
• 6775-78-6 6-chloroimidazo[1,2-b]pyridazine 
• 107-20-0 2-chloroethanal 
• 59772-58-6 3-aminopyridazine-6-carboxylic acid 

Relevant academic research and scientific papers

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.